Standard

CAR T-cell therapy : Balance of efficacy and safety. / Kulemzin, S. V.; Kuznetsova, V. V.; Mamonkin, M. et al.

In: Molecular Biology, Vol. 51, No. 2, 01.03.2017, p. 237-250.

Research output: Contribution to journal › Review article › peer-review

Harvard

Kulemzin, SV, Kuznetsova, VV, Mamonkin, M, Taranin, AV & Gorchakov, AA 2017, 'CAR T-cell therapy: Balance of efficacy and safety', Molecular Biology, vol. 51, no. 2, pp. 237-250. https://doi.org/10.1134/S0026893317020145

APA

Kulemzin, S. V., Kuznetsova, V. V., Mamonkin, M., Taranin, A. V., & Gorchakov, A. A. (2017). CAR T-cell therapy: Balance of efficacy and safety. Molecular Biology, 51(2), 237-250. https://doi.org/10.1134/S0026893317020145

Vancouver

Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA. CAR T-cell therapy: Balance of efficacy and safety. Molecular Biology. 2017 Mar 1;51(2):237-250. doi: 10.1134/S0026893317020145

Author

Kulemzin, S. V. ; Kuznetsova, V. V. ; Mamonkin, M. et al. / CAR T-cell therapy : Balance of efficacy and safety. In: Molecular Biology. 2017 ; Vol. 51, No. 2. pp. 237-250.

BibTeX

@article{309dcd6df9834acf98f0739ef4d81dcf,
title = "CAR T-cell therapy: Balance of efficacy and safety",
abstract = "Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.",
keywords = "adoptive immunotherapy, cancer, chimeric antigen receptor, T cells",
author = "Kulemzin, {S. V.} and Kuznetsova, {V. V.} and M. Mamonkin and Taranin, {A. V.} and Gorchakov, {A. A.}",
year = "2017",
month = mar,
day = "1",
doi = "10.1134/S0026893317020145",
language = "English",
volume = "51",
pages = "237--250",
journal = "Molecular Biology",
issn = "0026-8933",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "2",

}

RIS

TY - JOUR

T1 - CAR T-cell therapy

T2 - Balance of efficacy and safety

AU - Kulemzin, S. V.

AU - Kuznetsova, V. V.

AU - Mamonkin, M.

AU - Taranin, A. V.

AU - Gorchakov, A. A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

AB - Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

KW - adoptive immunotherapy

KW - cancer

KW - chimeric antigen receptor

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85019156977&partnerID=8YFLogxK

U2 - 10.1134/S0026893317020145

DO - 10.1134/S0026893317020145

M3 - Review article

AN - SCOPUS:85019156977

VL - 51

SP - 237

EP - 250

JO - Molecular Biology

JF - Molecular Biology

SN - 0026-8933

IS - 2

ER -

ID: 12197471